Loading stock data…
PolyPid Ltd (PYPD)
$5.33-0.06 (-1.11%)
Market ClosedLast close Sep 8
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PolyPid Ltd. in the Healthcare sector is trading at $5.33 with a market capitalization of $90M. Wall Street consensus targets $11.75 (4 analysts), implying a +120.5% move over the next 12 months. The stock is currently near its 52-week high of $5.73, remaining 18.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +120.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$7.58M↑ | -$9.40M↓ | -$7.46M↑ | -$8.53M↓ | -$7.76M |
| Net Income | -$8.27M↑ | -$9.98M↓ | -$7.45M↑ | -$8.47M↓ | -$7.73M |
Peer Comparison
JNJUNHPFE
Fundamentals
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$90.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-383.02%
Volume
Today's trading volume
87,311
Recent News
PolyPid (PYPD) Q2 2026 Earnings Call Transcript
FDA accepts D-PLEX100 application with Priority Review, setting November approval target.
PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ...
PolyPid secures FDA Priority Review for D-Plex 100 and a $30 million upfront partnership with Azurity, positioning the company for a potential early 2027 commercial launch.
PolyPid Ltd. Q2 2026 Earnings Call Summary
Moby summary of PolyPid Ltd.'s Q2 2026 earnings call
PolyPid Q2 Earnings Call Highlights
PolyPid (NASDAQ:PYPD) said its second-quarter 2026 was marked by the FDA’s acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada. D-PLEX100 is being developed to prevent surgical site infections in p
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
PolyPid Ltd (PYPD) progresses with NDA submission and strategic partnerships, despite reporting a net loss and decreased cash reserves.